Please login to the form below
venture capital
This page shows the latest venture capital news and features for those working in and with pharma, biotech and healthcare.
UK biotech funding falls 40% between 2018 and 2019
Out of that amount, £679m was raised in venture capital, £64m was raised in Initial Public Offerings (IPOs) and £596m in all other public financings. ... According to the report, global venture capital deals totalled £14.5bn in 2019, down 12%, with
Latest news
-
Merck acquires pre-clinical biotech Calporta for up to $576m
Calporta was one of eight San Diego-based biotechs created as part of a deal between venture capital firm Avalon Ventures and pharma giant GlaxoSmithKline. ... COI Pharmaceuticals is the venture-pharma entity established by Avalon to support its
-
Amgen exits neuroscience R&D to focus on growth areas
example through its collaboration with deCode Genetics, and will be “exploring potentially different models for doing that with venture capital and perhaps academic institutions as well”.
-
Biogen’s R&D chief Ehlers heads for the exit
Along with his CEO role at Limelight, Ehlers is also taking on a CSO position at venture capital firm Apple Tree.
-
Johnson pledges £200m cash injection into UK’s life sciences sector
The investment aims to help companies within the sector to raise capital – to run clinical trials, employ more industrial scientists and develop manufacturing capabilities. ... He added “this is particularly important in the coming weeks as UK-based
-
Mega-mergers dominate as buoyant markets lift biopharma
Venture capital is also fuelling biotech funding, with $3bn raised in Q2.
More from news
Approximately 2 fully matching, plus 106 partially matching documents found.
Latest Intelligence
-
AI: the smart money is on the smart thinking
This is coupled with venture capital (VC) being increasingly attracted to the sector. ... Therefore, it is highly likely that Big Pharma and venture capital will continue to target AI-focused companies in the coming months and years.
-
The search for treatments for Parkinson’s disease
is ignited by smaller biotechs, funded by venture capital, start-ups and academia. ... Pfizer itself established a venture capital organisation to fund early-stage projects.
-
Can protein degraders unlock ‘undruggable’ drug targets?
It raised $30m in its series A in 2017, and followed that up with a second-round fundraising last November that raised $67m and added Pfizer and Sanofi’s venture capital
-
BRIC markets
The country is attracting increasing amounts of venture capital funding and we are going see some novel medicines developed in those labs being sold in international markets,” he concluded.
-
Driving the innovation engine
Rapid changes in technology and the increasing availability of venture capital and angel investors now mean that if an employee has a good idea, he or she can rapidly capitalise on ... The boundary is that it’s limited to the stakeholders – including,
More from intelligence
Approximately 0 fully matching, plus 25 partially matching documents found.
Latest appointments
-
New hires at EMA, Gilead and BeiGene
Most recently, Grant was chief executive officer of the Dementia Discovery Fund (DDF), a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease.
-
AstraZeneca taps internal candidate to become UK president
Prior to joining AZ, Keith-Roach worked in technology venture capital and strategy consulting for a period of ten years.
-
Recruiters PIR International appoint four new executives
He has a track record of delivering global retained search assignments at executive and board level, partnering with venture capital and private equity funded growth stage businesses to drive patient centric
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
He has held roles for Hovione Capital, a life science focused venture capital company, and has served on several life science company boards.
-
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more
Brown succeeds Graham Boulnois, the group’s founding chairman, and brings experience of academic research, biotech, big pharma and US venture capital to the role. ... capital and financial markets. “His deep industry expertise, experience in oncology
More from appointments
Approximately 0 fully matching, plus 24 partially matching documents found.
Latest from PMHub
-
Random42 Attending Jefferies 2018 London Healthcare Conference
This global gathering of leading healthcare executives and institutional, private equity and venture capital investors will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare.
-
Random42 appoints Bill Collis as Chairman
He has vast experience in venture capital and private equity funding, intellectual property licensing, mergers and acquisitions and accessing international markets.
-
Managing value: Why early asset development and commercialization is important
Investors understand that it’s a gamble, but like every gambler they want the best odds. The figures really are staggering: there are companies with assets in development that have capital ... But while venture capital investors are pumping many
-
Big Bear Communications
We are a Strategic Marketing Consultancy to the pharmaceuticals / biotech sector and our clients include companies from the sector as well as those from the Venture Capital / Private Equity sector.
-
BigBear Communications Ltd
We are a Strategic Marketing Consultancy to the pharmaceuticals / biotech sector and our clients include companies from the sector as well as those from the Venture Capital / Private Equity sector.
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- FDA hands BMS and bluebird bio a priority review for ide-cel
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Keytruda doubles five-year survival rate in NSCLC
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
- Q&A: Isabel Gibson
PMHub
CSafe Global
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
